Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform

10 Sept 2015

Abstract excerpt

UNLABELLED: In 2012, the first cases of infection with the Middle East respiratory syndrome coronavirus (MERS-CoV) were identified. Since then, more than 1,000 cases of MERS-CoV infection have been confirmed; infection is typically associated with considerable morbidity and, in approximately 30% of cases, mortality. Currently, there is no protective vaccine available. Replication-competent recombinant measles...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune responses and vaccinations
Share to SARS-CoV-2 and COVID-19 Research
Share to Virology and Viral Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26355094
DOI: 10.1128/jvi.01815-15

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine PlatformPMID 26355094Read ↗

A Highly Immunogenic Measles Virus-based Th1-biased COVID-19 VaccineSemantic proximity Read ↗

Versatility of live-attenuated measles viruses as platform technology for recombinant vaccinesSemantic proximity Read ↗

Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing AntibodiesSemantic proximity Read ↗

Recombinant adenoviral vaccine encoding the spike 1 subunit of the Middle East Respiratory Syndrome Coronavirus elicits strong humoral and cellular immune responses in miceSemantic proximity Read ↗

CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in MiceSemantic proximity Read ↗

Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protectiveSemantic proximity Read ↗

Extracellular vesicle-based vaccine platform displaying native viral envelope proteins elicits a robust anti-SARS-CoV-2 response in miceSemantic proximity Read ↗

Immunogenicity of DNA vaccine encoding spike protein against Middle East respiratory syndrome coronavirus in mammalian modelSemantic proximity Read ↗

A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concernSemantic proximity Read ↗

Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variantsSemantic proximity Read ↗

Engineering a Replication-Competent, Propagation-Defective Middle East Respiratory Syndrome Coronavirus as a Vaccine CandidateSemantic proximity Read ↗

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccinationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.